Zhi Quan Tay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhi Quan Tay has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Ren Yi Seah
Department of Orthopaedic Surgery, Sengkang General Hospital, Singapore
1 shared publication - Chin Hong Ben Tan
Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore S117597, Singapore
1 shared publication - Chin Sheng Teoh
Department of Ophthalmology, Ng Teng Fong General Hospital, National University Health System, Singapore 119074, Singapore
1 shared publication - Craigven Hao Sheng Sim
Department of Orthopaedic Surgery, Singapore General Hospital, Outram Road, Singapore, 169608
1 shared publication Gheslynn Gerard
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
1 shared publicationGrace Wei Min Chew
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
1 shared publication
Latest Publications
- 14 December 2024
- Published by Springer Nature in Eye
- Vol. 39 (3) , 460-467
Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes. A review of relevant studies from PubMed, EMBASE, and Open Access databases was conducted, focusing on studies investigating the role of MTX in PVR. Study characteristics, patient demographics, dosages, administration frequency, and patient outcomes were extracted. Vitrectomy with various additional procedures such as laser photocoagulation, scleral buckling, gas tamponade and membranectomy were performed during primary and repeated surgery. Among the 180 eyes studied, those receiving MTX through intravitreal injection or intraoperative infusion showed promising outcomes, with retinal reattachment rates ranging from 74 to 92%. Eyes that received MTX infusion intraoperatively had an average retinal reattachment rate of 85%. Improvement in Best Corrected Visual Acuity was also observed in all eyes receiving MTX, with low rates of adverse events reported. Re-operation rates for repeated retinal detachment is significantly lower at 18% for eyes that received MTX treatment compared to those who did not receive MTX at initial surgery. Despite positive findings, further research is needed due to limitations such as small number of studies, low quality of evidence, and heterogeneity in treatment regimens. While MTX shows potential as an adjunctive treatment for PVR in RRD, more robust studies are necessary to confirm its efficacy.
- 14 December 2024
- Published by Springer Nature in Eye
- Vol. 39 (3) , 460-467
Efficacy and safety of methotrexate in the treatment of proliferative vitreoretinopathy: a systematic review
Proliferative Vitreoretinopathy (PVR) is a major complication of surgical repair for Rhegmatogenous Retinal Detachment (RRD). Methotrexate (MTX), a folate antimetabolite, has shown promise in targeting the pathological processes involved in PVR, such as cell proliferation inhibition, fibrosis and anti-inflammation. Systematic review examines the use of MTX in PVR by analysing different administration methods and outcomes. A review of relevant studies from PubMed, EMBASE, and Open Access databases was conducted, focusing on studies investigating the role of MTX in PVR. Study characteristics, patient demographics, dosages, administration frequency, and patient outcomes were extracted. Vitrectomy with various additional procedures such as laser photocoagulation, scleral buckling, gas tamponade and membranectomy were performed during primary and repeated surgery. Among the 180 eyes studied, those receiving MTX through intravitreal injection or intraoperative infusion showed promising outcomes, with retinal reattachment rates ranging from 74 to 92%. Eyes that received MTX infusion intraoperatively had an average retinal reattachment rate of 85%. Improvement in Best Corrected Visual Acuity was also observed in all eyes receiving MTX, with low rates of adverse events reported. Re-operation rates for repeated retinal detachment is significantly lower at 18% for eyes that received MTX treatment compared to those who did not receive MTX at initial surgery. Despite positive findings, further research is needed due to limitations such as small number of studies, low quality of evidence, and heterogeneity in treatment regimens. While MTX shows potential as an adjunctive treatment for PVR in RRD, more robust studies are necessary to confirm its efficacy.
- Open Access
- 14 December 2023
- Published by Elsevier in JSES International
- Vol. 8 (2) , 378-383
Targeted four-dimensional computerized tomography scans for elbow disorders: a literature review and refinement of existing technique with two exemplar cases
- 14 December 2023
- Published by Elsevier in JSES International
- Vol. 8 (2) , 378-383
Open AccessTargeted four-dimensional computerized tomography scans for elbow disorders: a literature review and refinement of existing technique with two exemplar cases
- Open Access
- 13 October 2023
- Published by Elsevier in Journal of ISAKOS
- Vol. 9 (2) , 192-204
Arthroscopic and open approaches for autologous matrix-induced chondrogenesis repair of the knee have similar results: a meta-analysis
- 13 October 2023
- Published by Elsevier in Journal of ISAKOS
- Vol. 9 (2) , 192-204
Open AccessArthroscopic and open approaches for autologous matrix-induced chondrogenesis repair of the knee have similar results: a meta-analysis